102252-89-1

Basic information

• Product Name: 3-amino-1-(4-methoxyphenyl)but-2-en-1-one
• Synonyms: 3-amino-1-(4-methoxyphenyl)but-2-en-1-one
• CAS NO: 102252-89-1
• Molecular Weight: 191.23
• Mol File: 102252-89-1.mol
• Article Data: 7

Chemical Properties

• CAS DataBase Reference: 3-amino-1-(4-methoxyphenyl)but-2-en-1-one(CAS DataBase Reference)
• NIST Chemistry Reference: 3-amino-1-(4-methoxyphenyl)but-2-en-1-one(102252-89-1)
• EPA Substance Registry System: 3-amino-1-(4-methoxyphenyl)but-2-en-1-one(102252-89-1)

Safety Data

• Hazardous Substances Data: 102252-89-1(Hazardous Substances Data)

Upstream product

• 4023-80-7 1-(4-methoxyphenyl)butan-1,3-dione 
• 631-61-8 ammonium acetate 

Relevant articles and documents

Design, Synthesis, and Crystallization-Induced Emission of Boron Difluorides β-Ketoiminates

A series of new nitrogen-containing analogues of boron difluoride benzoylacetonates with hydrogen and methyl substituents at the nitrogen atom have been synthesized. A comparative study of boron difluoride β-ketoiminates and their oxygen-containing analogues by means of luminescence and IR spectroscopic methods as well as quantum chemistry simulations was also performed.

Copper-Catalyzed Reductive Ring-Cleavage of Isoxazoles: Synthesis of Fluoroalkylated Enaminones and Application for the Preparation of Celecoxib, Deracoxib, and Mavacoxib

We have identified a new reactivity of copper/diamine catalysis for the reductive ring-cleavage of isoxazoles to yield fluoroalkylated enaminones. This protocol has the advantage of using commercially available reagents, ease of setting up, broad tolerance of functionality, and is regiospecific and free of defluorination and reduction of reducible functional groups. The utility was demonstrated by a one-step, regioselective synthesis of fluoroalkylated pyrazole-based drugs such as celecoxib, deracoxib, and mavacoxib.

NOVEL DUAL ACTION RECEPTORS ANTAGONISTS (DARA) AT THE AT1 AND ETA RECEPTORS

The present invention relates to new compounds of the formula [Chemical formula should be inserted here. Please see paper copy] wherein R1, R2, R3, and R31 are as specified herein. The invention also relates to a method for preparation thereof, as well as combinations of the new compounds with previously known agents. The invention also relates to the use of the above-mentioned compounds and combinations for the preparation of a medicament for treating hypertension of different kinds, alleviating organ damage of different kinds, treating or preventing diabetic nephropathy, treating endothelin and angiotensin mediated disorders, and treating prostate cancer.